DTM™ SCS endurance therapy Spinal cord stimulation
DTM™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.
Download clinical resultsYour browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
DTM™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.
Download clinical resultsInspired by science
DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.*2
Clinical results show meaningful pain relief
Study objectives
DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1
Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.
Secondary objectives with follow up to 12-months:
Study outcomes
Meaningful
pain relief
3.9
reduction in VAS for overall pain
from baseline to 3 months1
Meaningful quality of
life improvements
63%
of patients had minimal to moderate disability
at 3 months compared to only 16% at baseline1
Therapy satisfaction
75%
of patients are very or somewhat
satisfied with therapy1
Long lasting
5½-7½
years of recharge-free longevity
estimated using actual 3-month
programming data3
Save time
5 minutes
estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3
DTM™ SCS offers proven pain relief backed by data on Intellis™ SCS. Learn about the therapy.
See DTM™ SCSHigh performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.
Learn moreRapid recharge available with DTM™ SCS or DTM™ SCS endurance therapy.
Discover Intellis™ SCS*Note: Data obtained from animal studies should not be extrapolated to clinical/human results.
Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients: Primary endpoint and 3-month outcomes. Poster presented at: North american neuromodulation society (NANS) annual meeting. Jan. 13-15, 2022.
Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22-25, 2021.
Provenzano, Amirdelfan, Grewal, et al. Modeling energy demands of a reduced-energy derivative of differential target multiplexed™ stimulation on rechargeable and recharge-free systems. Poster presented at North American Neuromodulation Society (NANS). January 13-15, 2022.